Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Camp4 Therapeutics Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
2. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, based on the following votes: For Against Abstain 39,998,507 127 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Camp4 Therapeutics Corp shareholders approved Amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan at the 2026-06-10 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
3. The stockholders approved the amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan, based on the following votes: For Against Abstain Broker Non-Votes 27,002,145 10,023,588 199,455 2,773,446
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Camp4 Therapeutics Corp shareholders approved Election of Class II directors at the 2026-06-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
1. The following nominees were elected as the Company’s Class II directors, each to serve for a three-year term until the 2029 annual meeting of stockholders, and until his successor shall have been duly elected and qualified, based on the following votes: Nominees For Against Abstain Broker Non-Votes Steven Holtzman 29,233,042 7,992,146 — 2,773,446 Murray Stewart, DM FRCP 31,669,512 5,555,665 11 2,773,446 Richard Young, PhD 29,212,962 8,012,214 12 2,773,446
View on SEC.gov